Skip to main content

Advertisement

SpringerLink
Log in

Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

The risk of hip and other fractures was examined among a population-based group of older women with breast cancer. Women using aromatase inhibitors (AIs) were found to be over three times more likely to have a hip fracture over approximately 3 years’ follow-up. Other fracture risk factors were also identified.

Introduction

Aromatase inhibitors have been shown in randomized trials to increase total fracture risk compared with tamoxifen, but the fracture risks in the trials were relatively low, and no difference in hip fracture has been demonstrated.

Methods

A population-based cohort of 2003 breast cancer survivors ≥65 were followed prospectively for a median of 36 months. Patient survey information regarding adjuvant breast cancer therapies, prescription osteoporosis treatments, and other factors potentially associated with fracture was supplemented with cancer registry information. Hip and total nonvertebral fractures were determined using a validated Medicare algorithm, and the association of these fractures with adjuvant hormonal therapies was examined using Cox models.

Results

The cohort of 2,748 women with a mean age of 72.8 (SD 5.4) included 28.2% who took an aromatase inhibitor and 27.8% tamoxifen. There were 41 hip fractures (1.5%) and 218 nonvertebral fractures (7.9%) among the cohort. Subjects using AIs (adjusted hazard ratio 3.24 (1.05, 9.98)) and subjects not using hormone therapy (3.32 (1.14, 9.65)) were more likely than users of tamoxifen to have a hip fracture. Bisphosphonate use was more common among AI users but did not explain these results. Users of AIs were more likely to have nonvertebral fractures, but this result did not reach statistical significance (adjusted hazard 1.34 (0.92, 1.94)).

Conclusions

Hip and other fractures were common in an older population-based cohort of breast cancer survivors, and aromatase inhibitor use was associated with an increase in the short-term risk of hip fractures not detected in randomized controlled trials

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New England Journal of Medicine 349:1793–1802 [see comment]

    Article  PubMed  CAS  Google Scholar 

  2. Coates AS, Keshaviah A, Thurlimann B et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. Journal of Clinical Oncology 25:486–492 [see comment]

    Article  PubMed  CAS  Google Scholar 

  3. Coombes RC, Kilburn LS, Snowdon CF et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. The Lancet 369:559–570

    Article  CAS  Google Scholar 

  4. Jakesz R, Jonat W, Gnant M et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. The Lancet 366:455

    Article  CAS  Google Scholar 

  5. Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62 [see comment]

    Article  PubMed  CAS  Google Scholar 

  6. Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291:2720–2726

    Article  PubMed  CAS  Google Scholar 

  7. Lewis JH, Kilgore ML, Goldman DP et al (2003) Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21:1383–1389

    Article  PubMed  Google Scholar 

  8. Boccardo F, Rubagotti A, Puntoni M et al (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian tamoxifen anastrozole trial. J Clin Oncol 23:5138–5147

    Article  PubMed  CAS  Google Scholar 

  9. Baum M, Budzar AU, Cuzick J et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139 [see comment][erratum appears in Lancet 2002 Nov 9;360(9344):1520]

    Article  PubMed  CAS  Google Scholar 

  10. Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092

    Article  PubMed  CAS  Google Scholar 

  11. Crivellari D, Sun Z, Coates AS et al (2008) Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the big 1–98 trial. Journal of Clinical Oncology 26:1972–1979

    Article  PubMed  CAS  Google Scholar 

  12. U.S. Department of Health and Human Services (2004) Bone health and osteoporosis: a report of the surgeon general. Office of the Surgeon General, U.S. Department of Health and Human Services, Rockville

    Google Scholar 

  13. Cooper C, Melton LJ (1992) Epidemiology of osteoporosis. Trends Endocrinol Metab 3:224–229

    Article  PubMed  CAS  Google Scholar 

  14. Leibson CL TA, Gabriel SE, Ransom JE, Melton LJ (2002) Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc 50:1644–1650

    Article  PubMed  Google Scholar 

  15. Powles T, Hickish T, Kanis J et al (1996) Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78–84

    PubMed  CAS  Google Scholar 

  16. Love RR, Mazess RB, Barden HS et al (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. New England Journal of Medicine 326:852–856

    Article  PubMed  CAS  Google Scholar 

  17. Kristensen B, Ejlertsen B, Dalgaard P et al (1994) Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. Journal of Clinical Oncology 12:992–997

    PubMed  CAS  Google Scholar 

  18. Lonning PE, Geisler J, Krag LE et al (2005) Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23:5126–5137

    Article  PubMed  Google Scholar 

  19. Early Breast Cancer Trialists’ Collaborate Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467

    Article  Google Scholar 

  20. Pezzin LE, O’Niel M, Nattinger AB (2009) The economic consequences of breast cancer adjuvant hormonal treatments. J Gen Intern Med 24(Suppl 2):446–450

    Article  Google Scholar 

  21. Yen T, Fan X, Sparapani R, Laud P, Walker A, Nattinger A (2009) A contemporary, population-based study of lymphedema risk factors in older women with breast cancer. Ann Surg Oncol 16:979–988

    Article  PubMed  Google Scholar 

  22. Nattinger AB, Laud PW, Bajorunaite R, Sparapani RA, Freeman JL (2004) An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Services Research 39:1733–1749

    Article  PubMed  Google Scholar 

  23. Nattinger AP, Pezzin LE, Sparapani RA, Neuner JM, King TK, Laud PW (2010) Heightened attention to medical privacy: challenges for unbiased sample recruitment, and one solution. Am J Epidemiol 172:637–644

    Article  PubMed  Google Scholar 

  24. Neuner JM, Zhang X, Sparapani R, Laud PW, Nattinger AB (2007) Racial and socioeconomic disparities in bone density testing before and after hip fracture. J Gen Intern Med 22:123–145

    Article  Google Scholar 

  25. Ray WA, Griffin MR, Fought RL, Adams ML (1992) Identification of fractures from computerized Medicare files. J Clin Epidemiol 45:703–714

    Article  PubMed  CAS  Google Scholar 

  26. Curtis JR, Mudano AS, Solomon DH, Xi J, Melton ME, Saag KG (2009) Identification and validation of vertebral compression fractures using administrative claims data. Medical Care 47:69–72

    Article  PubMed  Google Scholar 

  27. Chen Z et al (2004) Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Women’s Health Initiative observational study and clinical trials. Menopause 11:264–274

    Article  PubMed  Google Scholar 

  28. Siris ES, Miller PD, Barrett-Connor E et al (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the national osteoporosis risk assessment. JAMA 286:2815–2822

    Article  PubMed  CAS  Google Scholar 

  29. Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D (2007) A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 17:584–590

    Article  PubMed  Google Scholar 

  30. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53

    Article  PubMed  Google Scholar 

  31. Cummings SR (1995) Risk factors for hip fracture in white women. N Engl J Med 322:767–773

    Article  Google Scholar 

  32. Barrett-Connor E, Siris ES, Wehren LE et al (2005) Osteoporosis and fracture risk in women of different ethnic groups. Journal of Bone & Mineral Research 20:185–194

    Article  Google Scholar 

  33. Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. Journal of the National Cancer Institute 90:1371–1388 [see comment]

    Article  PubMed  CAS  Google Scholar 

  34. Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. Journal of the National Cancer Institute 97:1652–1662

    Article  PubMed  CAS  Google Scholar 

  35. Kristensen B, Ejlertsen B, Mouridsen HT, Andersen KW, Lauritzen JB (1996) Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat 39:321–326

    Article  PubMed  CAS  Google Scholar 

  36. Perez EA, Josse RG, Pritchard KI et al (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 24:3629–3635

    Article  PubMed  CAS  Google Scholar 

  37. Melton Iii LJ, Crowson CS, O’Fallon WM (1999) Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporosis International 9:29–37

    Article  Google Scholar 

  38. Brufsky A, Bundred N, Coleman R et al (2008) Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13:503–514

    Article  PubMed  CAS  Google Scholar 

  39. Greenspan SL, Brufsky A, Lembersky BC et al (2008) Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 26:2644–2652

    Article  PubMed  CAS  Google Scholar 

  40. Brufsky A, Harker WG, Beck JT et al (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. Journal of Clinical Oncology 25:829–836

    Article  PubMed  CAS  Google Scholar 

  41. Woo S-B, Hellstein JW, Kalmar JR (2006) Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761

    PubMed  CAS  Google Scholar 

  42. Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. New Engl J Med 357:1799–1809

    Article  PubMed  CAS  Google Scholar 

  43. Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM (2008) Use of alendronate and risk of incident atrial fibrillation in women. Archives of Internal Medicine 168:826–831

    Article  PubMed  CAS  Google Scholar 

  44. Wysowski DK (2009) Reports of esophageal cancer with oral bisphosphonate use. New Engl J Med 360:89–90

    Article  PubMed  CAS  Google Scholar 

  45. Hillner BE (2004) Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 101:1311–1322

    Article  PubMed  Google Scholar 

  46. Locker GY, Mansel R, Cella D et al (2007) Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat 106:229–238

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by R21 CA131643-01A1, K07 CA125586-01A1, and PHS Grant R01 CA81379 from the National Institutes of Health.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA

    J. M. Neuner & A. B. Nattinger

  2. Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA

    T. W. Yen

  3. Center for Patient Care and Outcomes Research, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA

    J. M. Neuner, T. W. Yen, R. A. Sparapani, P. W. Laud & A. B. Nattinger

  4. Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA

    P. W. Laud

Authors
  1. J. M. Neuner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. W. Yen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. A. Sparapani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. W. Laud
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. B. Nattinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. M. Neuner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neuner, J.M., Yen, T.W., Sparapani, R.A. et al. Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients. Osteoporos Int 22, 2847–2855 (2011). https://doi.org/10.1007/s00198-010-1493-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-010-1493-x

Keywords

Search

Navigation